Actelion is preparing for transformational growth to benefit all stakeholders, putting processes and infrastructure in place that will take its novel chemical entities currently in late-stage development through to become innovative medicines for patients.
| Date | Event | Description |
| 21 Oct 2010 | Q3 Results 2010 | Webcast with financial results for the first 9 months of 2010 |
| 17 Feb 2011 | FY Results 2010 | Wecast with financial results for the Full Year results 2010 |
| 19 Apr 2011 | Q1 Results 2011 | Webcast with financial results for the first 3 months of 2011 |
| In CHF million | Results HY 2010 | Results HY 2009 | in % | |
| Net revenues | 1,024.9 | 855.2 | 20 | |
| Operating expenses | 698.2 | 612.4 | 14 | |
| Operating income | 326.6 | 242.9 | 34 | |
| Non-GAAP EBIT | 405.1 | 304.8 | 33 | |
| Net income | 254.2 | 218.4 | 16 | |
| Diluted EPS in CHF | 2.10 | 1.79 | 17 | |
| No of shares in calculation | 121.314 m | 122.340 m | n/a |
